A retrospective single-center study to determine effectiveness and safety in real clinical practice of drugs targeting the calcitonin gene-related peptide receptor in patients with chronic migraine
Latest Information Update: 24 Aug 2022
At a glance
- Drugs Erenumab (Primary) ; Fremanezumab (Primary) ; Galcanezumab (Primary)
- Indications Migraine
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 24 Aug 2022 New trial record
- 18 Aug 2022 Results published in the Annals of Pharmacotherapy